Human hair derived uPA loaded capsules with dual near-infrared (I and II biowindows) laser responsive capabilities for multi-effective thrombolysis therapy

Fang, Cuifu; Zhong, Zhiwei; Zhang, Teng; Jia, Shuang; Ding, Xingwei; Zhou, Weimin; Wang, Xiaolei

doi:10.1039/d0tb02242j

Cited by 11 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fang et al showed with their non-theranostic drug delivery system that it is possible however 93 . Here, a light-responsive hair-derived nanoparticle was loaded with urokinase, and encapsulated in gelatin, which melted and released the thrombolytic payload upon heating.…”

Section: Responsive Theranostic Nanocarriersmentioning

confidence: 99%

“…Here, a light-responsive hair-derived nanoparticle was loaded with urokinase, and encapsulated in gelatin, which melted and released the thrombolytic payload upon heating. This resulted in particles with a highly specific release profile, and their in vivo thrombolytic ability could be controlled through NIR radiation 93 . Hence, the adaptation of such a system to also exhibit imaging functionality may result in a highly promising theranostic approach.…”

Section: Responsive Theranostic Nanocarriersmentioning

confidence: 99%

See 1 more Smart Citation

Theranostic nanoparticles for the management of thrombosis

Russell¹,

Hagemeyer²,

Esser³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Acute thrombosis and thromboembolisms are one of the leading causes of mortality and morbidity in both developed and developing countries, placing a huge burden on health and economic systems. Early diagnosis is critical but currently limited in accuracy and hampered by a narrow time frame, where the short therapeutic window also severely restricts treatment options. Additionally, clinically used antithrombotics and thrombolytics suffer from severe side effects and are limited in efficacy by a short half-life and susceptibility to degradation. The use of systems containing both diagnostic and therapeutic moieties, known as theranostics, can potentially improve patient outcomes by increasing the precision and efficacy of diagnosis and treatment, enabling personalised and precision medicine. Leveraging nanomedicine may further improve treatment by improving the system's pharmacokinetic properties including controlled drug delivery. This review provides an overview of the development of such theranostic nanoparticle systems, with a focus on approaches that may be utilised to usher this field towards clinical use.

show abstract

Section: Responsive Theranostic Nanocarriersmentioning

confidence: 99%

Section: Responsive Theranostic Nanocarriersmentioning

confidence: 99%

Theranostic nanoparticles for the management of thrombosis

Russell¹,

Hagemeyer²,

Esser³

et al. 2022

Theranostics

View full text Add to dashboard Cite

show abstract

“…Under NIR illumination, photothermal agents or materials can convert light into heat, which can disrupt nanocarriers or their phase transitions, leading to rapid drug release. NIR illumination combined with up-conversion NPs has also been developed. − Wang et al developed a NIR-driven nanophotosynthetic biosystem that converts NIR light with excellent tissue penetration ability into visible light via up-conversion NPs to activate oxygen production by Streptococcus elongatus in vivo, enhance angiogenesis, reduce infarct size, and promote brain tissue repair. Thus, the nanophotosynthetic biosystem can improve thrombolytic efficiency, promote angiogenesis, and prevent thrombus recurrence.…”

Section: Nanotherapeutics For Ischemic Strokementioning

confidence: 99%

Recent Advances in Targeted Nanotherapies for Ischemic Stroke

Liao

Luo

et al. 2022

Mol. Pharmaceutics

View full text Add to dashboard Cite

Ischemic stroke (IS) is a severe neurological disease caused by the narrowing or occlusion of cerebral blood vessels and is known for high morbidity, disability, and mortality rates. Clinically available treatments of stroke include the surgical removal of the thrombus and thrombolysis with tissue fibrinogen activator. Pharmaceuticals targeting IS are uncommon, and the development of new therapies is hindered by the low bioavailability and stability of many drugs. Nanomedicine provides new opportunities for the development of novel neuroprotective and thrombolytic strategies for the diagnosis and treatment of IS. Numerous nanotherapeutics with different physicochemical properties are currently being developed to facilitate drug delivery by accumulation and controlled release and to improve their restorative properties. In this review, we discuss recent developments in IS therapy, including assisted drug delivery and targeting, neuroprotection through regulation of the neuron environment, and sources of endogenous biomimetic specific targeting. In addition, we discuss the role and neurotoxic effects of inorganic metal nanoparticles in IS therapy. This study provides a theoretical basis for the utilization of nano-IS therapies that may contribute to the development of new strategies for a range of embolic diseases.

show abstract

“…Cancer is responsible for approximately one in six deaths worldwide, − which seriously affects the health and quality of life of humans. , Targeted therapy is one of the most convenient treatment options, − although it has certain problems, such as poor patient universality and high economic costs. In view of this, patients need to be sorted and treated in the preclinical stage. − …”

Section: Introductionmentioning

confidence: 99%

Discovery of Imaging and Therapeutic Integration Bifunctional Molecules Based on Bio-Orthogonal Reaction and Releasable Disulfide Bond

Wang

Zhang

et al. 2022

Bioconjugate Chem.

View full text Add to dashboard Cite

The application of conventional fluorescent probes in living cells has been limited by excess fluorescence interference, reduced selectivity, and poor permeability. Herein, we describe a convenient solution for overcoming the above limitations based on bio-orthogonal reactions and releasable linkers that provide bifunctional molecules for imaging and therapeutic integration. To reduce the interference of excess fluorescent moieties, a bioorthogonal reaction was applied to activate the fluorescence of the active parent drugs without fluorophores. Moreover, disulfide bonds were incorporated as releasable linkers. After imaging the target protein, the newly yielded fluorophore could be released from the active drugs based on the highly reducing conditions of the tumor. Thus, these bifunctional molecules are comparable in therapeutic activity to the parent drug. These novel imaging and therapeutic integration molecules could be used to realize imagingaided diagnosis and perform efficient real-time monitoring of cancer cells. Our findings are expected to enable efficient and specific imaging and real-time in vivo prognostic monitoring in the clinic.

show abstract

Human hair derived uPA loaded capsules with dual near-infrared (I and II biowindows) laser responsive capabilities for multi-effective thrombolysis therapy

Abstract: Problems such as massive hemorrhage caused by uncontrolled drug dosage are the main significant obstacle in clinical thrombolytic therapy, which are prominently due to the lack of targeting and controlled...

Cited by 11 publications

References 36 publications

Theranostic nanoparticles for the management of thrombosis

Theranostic nanoparticles for the management of thrombosis

Recent Advances in Targeted Nanotherapies for Ischemic Stroke

Discovery of Imaging and Therapeutic Integration Bifunctional Molecules Based on Bio-Orthogonal Reaction and Releasable Disulfide Bond

Contact Info

Product

Resources

About